首页|血清cathepsin S、ANGPTL3、HN水平与冠心病患者病情程度及预后的相关性分析

血清cathepsin S、ANGPTL3、HN水平与冠心病患者病情程度及预后的相关性分析

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
目的 探讨冠心病患者血清组织蛋白酶S(cathepsin S)、血管生成素样蛋白 3(ANGPTL3)、抗凋亡多肽(HN)水平与病情程度相关性及其对预后的预测价值.方法 选取经皮冠状动脉介入术(PCI)治疗的 126 例冠心病患者为研究组,依据不同病变支数分为单支病变 45 例、双支病变 42 例、多支病变 39 例,另选取 42 例同期健康体检者为对照组.比较两组血清cathepsin S、ANGPTL3、HN水平.比较研究组不同病变支数者血清cathepsin S、ANGPTL3、HN水平及Gensini评分.分析血清cathepsin S、ANGPTL3、HN水平与病变支数、Gensini评分相关性.依据研究组治疗后 6 个月内预后情况分为预后不良者、预后良好者,比较其血清cathepsin S、ANGPTL3、HN水平.采用多因素Logistic回归分析预后不良的影响因素,采用受试者工作特征曲线(ROC)分析各血清指标单项及联合对预后不良的预测价值.结果 研究组血清cathepsin S、ANGPTL3 水平高于对照组,HN水平低于对照组(P＜0.05);随着病变支数增加,血清cathepsin S、ANGPTL3 水平及Gensini评分呈上升趋势,HN水平呈下降趋势(P＜0.05);血清cathepsin S、ANGPTL3 与病变支数、Gensini评分呈正相关,而HN与之相反(P＜0.05);治疗后 1 个月,预后不良者血清cathepsin S、ANGPTL3 水平高于预后良好者,HN水平低于预后良好者(P＜0.05);年龄、血清NT-proBNP及治疗后 1 个月血清cathepsin S、ANGPTL3 水平为预后不良的独立危险因素,LVEF及治疗后 1 个月血清HN水平为预后不良的独立保护因素(P＜0.05);cathepsin S、ANGPTL3、HN联合预测预后不良的AUC大于单项指标预测(P＜0.05).结论 冠心病患者血清cathepsin S、ANGPTL3 水平升高,而血清HN水平降低,且与病情严重程度、预后密切相关,联合检测其水平对预后不良具有一定预测价值.
Correlation analysis of serum cathepsin S,ANGPTL3 and HN levels with the severity and prognosis of patients with coronary heart disease
Objective To investigate the correlation between serum levels of cathepsin S,angiopoietin-like protein 3(ANGPTL3)and anti-apoptotic polypeptide(HN)and their predictive value in patients with coronary heart disease and the severity of the disease.Methods A total of 126 patients with coronary heart disease who underwent percutaneous coronary intervention(PCI)were selected as the study group,and were divided into 45 cases of single lesions,42 cases of double lesions,and 39 cases of multiple lesions according to the number of lesions,and 42 patients with healthy examination in the same period were selected as the control group.The serum levels of cathepsin S,ANGPTL3 and HN were compared between the two groups.The serum levels of cathepsin S,ANGPTL3,HN and Gensini score were compared in the study group.The correla-tion between serum levels of cathepsin S,ANGPTL3 and HN and the number of lesions and Gensini score was analyzed.Ac-cording to the prognosis of the study group within 6 months after treatment,the patients with poor prognosis and those with good prognosis were divided,and the serum levels of cathepsin S,ANGPTL3 and HN were compared.Multivariate logistic re-gression was used to analyze the influencing factors of poor prognosis,and receiver operating characteristic curve(ROC)was used to analyze the predictive value of individual and combined serum indexes for poor prognosis.Results The serum levels of cathepsin S and ANGPTL3 in the study group were higher than those in the control group,and the levels of HN were lower than those in the control group(P<0.05 ANGPTL3<ANGPTL3).On the contrary,HN(P<0.05),the serum levels of cathepsin S and ANGPTL3 in patients with poor prognosis were higher than those with good prognosis at 1 month after treatment,and the levels of HN were lower than those with good prognosis(P<0.05 ANGPTL3).LVEF and serum HN level at 1 month after treatment were independent protective factors for poor prognosis(P<0.05),and the AUC of cathepsin S,ANGPTL3 and HN was greater than that predicted by individual indicators(P<0.05).Conclusion The serum levels of cathepsin S and ANGPTL3 are increased,while the serum HN level is decreased,which is closely related to the severity and prognosis of the disease.

Coronary heart diseaseCathepsin SAngiopoietin-like protein 3Anti-apoptotic peptidesPrognosisForecast

李俊峰、杨森、高强

展开 >

南阳张仲景医院急诊科,河南 南阳 473000

冠心病 组织蛋白酶S 血管生成素样蛋白3 抗凋亡多肽 预后 预测

2024

10.3969/j.issn.1001-8131.2024.04.013

哈尔滨医药
哈尔滨市医学会

哈尔滨医药

影响因子：0.697
ISSN：1001-8131
年,卷(期)：2024.44(4)
  • 10